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Objective To assess whether there was an adverse effect on brain growth after hydrocortisone (HC) treatment for
bronchopulmonary dysplasia (BPD) in a large cohort of infants without dexamethasone exposure.
Study design Infants who received HC for BPD between 2005 and 2011 and underwent magnetic resonance
imaging at term-equivalent age were included. Control infants born in Geneva (2005-2006) and Utrecht
(2007-2011) were matched to the infants treated with HC according to segmentation method, sex, and gestational
age. Infants with overt parenchymal pathology were excluded. Multivariable analysis was used to determine if there
was a difference in brain volumes between the 2 groups.
Results Seventy-three infants treated with HC and 73matched controls were included. Mean gestational age was
26.7 weeks, and mean birth weight was 906 g. After correction for gestational age, postmenstrual age at time of
scanning, the presence of intraventricular hemorrhage, and birth weight z-score, no differences were found be-
tween infants treated with HC and controls in total brain tissue or cerebellar volumes.
Conclusions In the absence of associated parenchymal brain injury, no reduction in brain tissue or cerebel-
lar volumes could be found at term-equivalent age between infants with or without treatment with HC for BPD.
(J Pediatr 2013;163:666-71).
B
ronchopulmonary dysplasia (BPD) remains a common complication of extremely preterm birth. Risk factors for the
development of BPD, such as difficulty in weaning an infant from the ventilator or prolonged oxygen requirement in
the first weeks of life, are even more frequently encountered. Treatment options are limited. If conservative care with
less aggressive ventilator settings, treatment of a hemodynamic significant patent ductus arteriosus, fluid restriction, and/or
diuretics is not sufficient, a decision can be made to treat with corticosteroids, with dexamethasone used most commonly. Al-
though the short-term effects of dexamethasone prescription on pulmonary function are satisfactory, effects on long-term neu-
rodevelopmental outcome are not.1 Preterm infants treated with dexamethasone had a higher rate of cerebral palsy and
cognitive impairment and more often needed special education at early school age.2-4 The origin of these adverse sequelae
may be represented by as smaller brain volumes at term-equivalent age.5,6 Therefore, treatment with dexamethasone is not rec-
ommended and should be restricted to the most severe cases.
Hydrocortisone (HC) is an alternative treatment option. Although somewhat less potent, if given moderately early (between
5-25 days after birth), the effects on pulmonary function are similar. There is notmuch research on long-term outcomes after the
use of HC, but several studies have not shown any difference betweenHC-treated infants and controls regarding rates of cerebral
palsy and other neuromotor deficits and cognitive development.7-10 Two studies have reported on the effect of HC on brain vol-
umes at term-equivalent age. Benders et al described a small cohort of preterm infants without associated brain injury and did not
find any differences betweenHC-treated infants and controls.11 However, Tam et al described a larger cohort and found a differ-
ence in cerebellar size at term-equivalent age after treatment withHC.12 Important drawbacks of the study by Tam et al were thatFrom the 1Department of Neonatology, Wilhelmina
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A combined cohort was formed containing children from
Geneva and Utrecht. Infants from Utrecht, who received
HC for BPD between 2005 and 2011 and had magnetic reso-
nance imaging (MRI) at term-equivalent age, were included.
Infants born between 2005-2006 have been described previ-
ously.11 For those previously described infants, parental in-
formed consent was given. For the other infants, clinically
indicated magnetic resonance (MR) images were used with
permission from the ethical review board of our institution.
HC was given starting at a postnatal age of $7 days, in
ventilator-dependent infants with need for supplemental
oxygen, if this could not be accounted for by an infection or
a patent ductus arteriosus. Standard clinical dosage schemes
were followed, starting with a dosage of 5 mg/kg/d divided
in 4 doses for 1 week and a subsequent tapering course every
5 days, leading to a total treatment duration of 22 days and
a standard cumulative dosage of 72.5 mg/kg. This scheme
could be adjusted at the discretion of the attending neonatol-
ogist. Infants treatedwithHCwerematched to control infants
born in both Geneva (2005-2006) and Utrecht (2007-2011).
Control infants were matched for sex and gestational age.
Matching was performed in subgroups, taking into account
that infants were matched with controls scanned with the
same imaging protocol and segmented with the same
automatic method. Clinical variables were extracted from
patient charts. Cerebral lesions were diagnosed on the basis
of serial cranial ultrasound and MRI results. The presence of
an intraventricular hemorrhage (IVH), graded according to
Papile et al,13 white matter damage, and large cerebellar hem-
orrhages was recorded. Infants with a large parenchymal hem-
orrhage (1 infant) or a large cerebellar hemorrhage (1 infant)
were excluded. In all infants with posthemorrhagic ventricu-
lar dilatation, a stable situation with a decrease in ventricular
size was reached soon after the initiation of treatment. Three
infants in the HC-treated group had a reservoir inserted but
none required a permanent shunt. There were no infants
with evidence of cystic periventricular leukomalacia on their
cranial ultrasound and MRI examinations.
MRI Examination
MRI was performed around term-equivalent age in all in-
fants. Infants born in 2005 and 2006 were scanned with use
of a 1.5-T MR system (Philips Medical Systems, Best, The
Netherlands). The protocol included a 3-dimensional (3D)
T1 fast-gradient echo sequence (repetition time [TR]
15 ms, echo time [TE] 4.4 ms, slice thickness 1.5 mm) and
a T2 fast-spin echo sequence (TR 3500 ms, TE 30/150 ms,
slice thickness 1.5 mm), both in the coronal plane.
Infants born in 2007 or later were scanned with use of
a 3.0-T MR system (Achieva; Philips Medical Systems) using
the sense head coil. Between 2007 and June 2008, the imaging
protocol contained axial 3D T1-weighted and T2-weighted
images (TR 9.4 ms, TE 4.6 ms, and slice thickness 2.0 mm;
and TR 6293 ms, TE 120 ms, and slice thickness 2.0 mm,respectively). From June 2008 on, 3D T1-weighted and T2-
weighted images were acquired in the coronal plane (3D
T1-weighted: TR 9.5 ms, TE 4.6 ms, and slice thickness
1.2 mm; 3D T2-weighted: TR 4847 ms, TE 150 ms, and slice
thickness 1.2 mm).
Infants were sedated using oral chloral hydrate 50-60 mg/
kg.Heart rate, transcutaneous oxygen saturation, and respira-
tory rate weremonitored.Minimuffs (NatusMedical Inc, San
Carlos, California) were used for hearing protection. All MR
examinations were reevaluated by 2 experienced neonatolo-
gists. Lesions seen on conventional imaging were scored. In-
fants with evident tissue loss on MRI (eg, porencephaly due
to a periventricular hemorrhagic infarction or a large cerebel-
lar lesion destroying more than one-half of the cerebellar
hemisphere) were excluded (2 patients, as described earlier).Volumetric Measurements
Brain tissue and cerebellum were segmented automatically.
Considering that infants were scanned using 2 different
imaging protocols on scanners of a different field strength,
we chose to use the segmentation method best fitted for the
acquisition of the data per imaging protocol. Therefore, seg-
mentations were performed using 2 different segmentation
methods. For the children born before 2007 in both Utrecht
and Geneva, tissues were segmented using the method de-
scribed by Warfield et al.14 The method segments cortical
gray matter, deep gray matter, unmyelinated white matter,
myelinated white matter, and cerebrospinal fluid, but it
does not allow separate delineation of the cerebellum. There-
fore, cerebellar tissue was manually outlined in T2-weighted
scans and volumes were corrected accordingly. Details from
this method have been described previously.11 For the infants
born in 2007 or later, the algorithm of the method of Anbeek
et al was adjusted to segment 3T scans.15,16 In addition to the
mentioned tissues, this algorithm delineates cerebellum,
basal ganglia, brainstem, and separation of the cerebrospinal
fluid in the ventricles from cerebrospinal fluid outside the
brain. Cerebellar segmentations in this group were thus
automatically generated. Total brain tissue volume and intra-
cranial volume were calculated from the segmentations. The
Anbeek et al15,16 method was developed for axially acquired
images. However, we tested for a difference in volumes be-
tween coronal and axial acquired images in a subgroup of 5
infants and did not find any differences in volumes (paired
t tests: cerebellum, P = .245; total brain volume, P = .783).
In addition, to confirm the quality of the automatically
obtained segmentations, results were visually inspected.
This allowed us to combine these sets into 1 cohort.Statistical Analyses
Statistical procedures were performed using both IBM SPSS
Statistics version 20 (SPSS Inc, Chicago, Illinois) and R ver-
sion 2.15.0 (www.r-project.org/).17 Baseline characteristics
between the 2 groups were compared using independent-
sample t tests. For multivariable analysis, general linear mod-
eling was used with brain volume as dependent variable. A667
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included, and a matched sample of all other patients without
HC use and with available MRI. Brain volumes were analyzed
with individual patients in the regression model. Earlier
studies reported a decrease in brain volume of 20% for cer-
ebellar volume and 10%-30% for total cerebral tissue volume
after the use of dexamethasone.5,6 Sample size calculations
were performed, taking into account the ability to show
the presence or absence of an effect one-half the size of dexa-
methasone, so a 10% difference in brain volumes. Sample
size calculations demonstrated that this difference of 10%
in brain volumes could be demonstrated with an a of
0.05, a power of 0.9, and a sample size of 55 patients in
each arm.
Because postmenstrual age at the time of scanning, gesta-
tional age, and birth weight influence total brain volumes, we
included these variables in our model.18-20 We also included
the presence of an IVH. Separate analysis of infants with mild
posthemorrhagic ventricular dilatation, minor punctate
white matter lesions, or punctate cerebellar hemorrhages re-
vealed no significant differences in volumes. Therefore, these
patients were included in the final analysis. Corticosteroid
use was analyzed in 2 ways: binomial (yes/no) and as total cu-
mulative dosage per kilogram up to the day of MRI. Because
distribution of HC was skewed, we used the natural loga-
rithm of this variable. Also, to screen whether a high dose
of HC would have an effect where a low dose did not, we re-
peated the analysis with HC divided as none, a cumulative
dosage <50 mg/kg, and a cumulative dosage >50 mg/kg. In-
teraction of gestational age and HC was tested in the model.
Postmenstrual age at time of scanning was calculated as theTable I. Clinical variables
Variable Infants t
Gestational age, wk (SD, range) 26.
Sex, No. male/female
Birth weight, g (SD)
Birth weight z score
Antenatal steroids, %
Mechanical ventilation, median d (25th-75th percentile)
Grade RDS, No.
None
Grade 1
Grade 2
Grade 3
Grade 4
Postmenstrual age at time of scanning, wk (SD)
Weight at time of scanning, g (SD)
Presence of IVH, No.
None
Grade 1-2
Grade 3
Grade 4
Cerebellar hemorrhage, No.
None
<6 Punctate lesions
>6 Punctate lesions
Posthemorrhagic ventricular dilatation requiring intervention, No.
Lumbar punctures
Placement of a reservoir
RDS, respiratory distress syndrome.
668difference from 40.0 weeks’ postmenstrual age and gesta-
tional age as the difference from 24.0 weeks’ (our youngest
included infants were born at that gestation). Birth weights
are represented using a z score. All statistical analyses were
also performed within each subgroup (eg, infants segmented
with the Warfield et al14 method and with the Anbeek
et al15,16 method) to further quantify any possible differences
between groups.
Results
A total of 75 infants treated with HC and 75 control infants
were included. Two infants treated with HC had evident tissue
loss on their MRI (1 porencephaly and 1 large cerebellar hem-
orrhage) and thus were excluded. The remaining 73 infants
withHC treatment and 73 control infantswere eligible for anal-
ysis. Despite matching, infants treated with HC had a signifi-
cantly lower birth weight (P = .01, Table I). Weight at scan,
however, did not differ significantly (P = .25). Concurrent
with the more severe pulmonary problems, the grade of
respiratory distress syndrome21 and days of mechanical
ventilation were significantly higher in infants treated with
HC compared with controls (P = .00 and P = .05,
respectively). Because HC was given as part of clinical
practice at the discretion of the attending neonatologist, not
all infants received the same cumulative dosage. In some
children, HC was tapered sooner because of significant
improvement or side effects such as hypertension. In other
infants, a longer treatment or a slower tapering course was
given because of a relapse after the first tapering steps. This
led to a wide range in the cumulative dosage of HC, betweenreated with HC (n = 73) Control infants (n = 73) P value
6 (1.35, 24.3-30.4) 26.9 (1.34, 24.3-30.4) .12
40/33 36/37 .51
863 (205) 948 (166) .01
0.06 0.40 .02
70 77 .70
16 (12-21) 4 (0-7) .05
.00
4 21
2 3
15 31
28 11
24 7
41.1 (0.76) 41.1 (0.75) .67
3182 (571) 3280 (459) .25
.001
41 60
24 12
7 1
0 0
.79
69 68
3 4
1 1
.05
3 1
3 0
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Table III. Multivariable analysis
Model/factor
Coefficient,
mL 95% CI
P
value
Total brain tissue volume: final model
Postmenstrual age at scan, wk 18.2 9.2 to 27.3 .00
Birth weight z score 11.2 3.3 to 19.2 .00
Gestational age, wk 6.8 1.7 to 12.0 .01
HC, yes/no 12.5 26.3 to 1.4 .08
Cerebellar volume: final model
Postmenstrual age at scan, wk 2.1 1.3 to 2.9 .00
Birth weight z score 2.2 1.6 to 2.9 .00
Grade 3 IVH 2.2 4.4 to 0.1 .06
HC, yes/no 0.53 1.8 to 0.7 .39
In the model, postmenstrual age is taken as the difference from 40 wk, and gestational age as
the difference from 24 wk. IVH is graded according to Papile et al.13
September 2013 ORIGINAL ARTICLES16 and 216 mg/kg with a mean of 77 mg/kg. Also, although
children with evidence of tissue loss were excluded, the
presence of an IVH did show a significant difference (P = .00,
Table I). The presence of an IVH may have an adverse effect
on cerebellar volumes.22 Therefore, the presence of a grade 3
IVH was included as a factor in the multivariable analysis.
There were no infants with evidence of cystic periventricular
leukomalacia on their cranial ultrasound and MRI in this
cohort.
Uncorrected brain volumes are shown in Table II (available
atwww.jpeds.com).The results of themultivariable analysis are
shown in Table III. There was no significant difference in total
brain tissue volume between HC-treated and control infants
(P = .08). Only postmenstrual age at MRI, birth weight z
score, and gestational age at birth were significant factors in
the multivariable model. Repeating the analysis using the
cumulative dosage of HC gave the same results (P = .1), as
did the analysis with HC divided into high and low dosages
(P = .11 and P = .28, respectively).
We also performed these analyses for cerebellar volumes,
because previous literature suggested that this brain structure
may especially be affected by the use of HC.12 Multivariable
analysis showed postmenstrual age at time of scan, birth
weight z score, and grade 3 IVH to be of significant influence
on cerebellar volumes at term-equivalent age. Again, neither
HC as a binomial factor (P = .39) nor the cumulative dosage
of HC (P = .07), or the divided dosages (P = .26 for the high
and P = .82 for the low dosage), were significant. Although
infants with large cerebellar hemorrhages were excluded,
we did include infants with punctate lesions in the cerebel-
lum. When repeating the analysis after exclusion of these
children, the resulting models were the same. Therefore,
these children remained included in the analysis.
The results of the subgroup analysis were identical to
those of the entire cohort and are therefore not represented
separately.
Discussion
In this cohort of 146 preterm infants, HC treatment for BPD
was not associated with a reduction in total brain tissue vol-
ume or cerebellar volume. Only postmenstrual age at time ofHydrocortisone Treatment for Bronchopulmonary Dysplasia andscanning, gestational age, and birth weight z score had
a significant effect on total brain tissue volume. Postmenst-
rual age at time of scanning, birth weight z score, and the
presence of a grade 3 IVH had a significant effect on the cer-
ebellar volumes at term-equivalent age. These are all known
factors to adversely affect brain volumes.18-20,22
The lack of effect of HC on brain volumes is consistent with
previous reports from our group describing short- and long-
term effects of HC. Benders et al described a small subset of
this cohort and were unable to find any differences in brain
volumes.11 This absence of volumetric differences seems to
persist into childhood. Lodygensky et al showed in a cohort
of 60 preterm children that brain volumes and neurocogni-
tive outcome at 8 years did not differ between children treated
with HC and preterm controls.23 The lack of effect of HC on
long-term neurodevelopmental outcome has also been
shown in several follow-up studies.7-10,24 In contrast, Tam
et al showed that in their cohort of 172 infants, cerebellar vol-
ume was negatively affected by the use of both dexametha-
sone and HC.12 However, only 31 subjects received
postnatal HC and 11 of those received both HC and dexa-
methasone. Also, infants with large cerebellar hemorrhages
were included in the analysis, although multivariable correc-
tion was used. Tam et al found a negative effect of 8% on cer-
ebellar volumes after the use of HC.12 Allin et al previously
reported an 8% decrease of cerebellar volume in preterm in-
fants compared with healthy term controls at 15 years of age.
This decrease had a negative correlation with long-term cog-
nitive outcome.25 An 8% difference, therefore, seems to have
clinical relevance. An additional power calculation demon-
strated that in our 146 patients, the power to detect a differ-
ence of 8% in brain volumes with an a of 0.05 would be 0.85.
In addition, based on the observations of dexamethasone, the
potential effect of HC is to diminish and not to increase brain
volumes, a 1-sided test could be used. In this case, the power
of our study of 146 infants divided over 2 groups of 73 would
be 0.92, which is high.
Previous studies on volumetric changes after dexametha-
sone use have shown decreases in cerebellar volume of 20%
and in total cerebral tissue volume of 10%-30%.5,6 The effect
sizes found in this study are, besides not being significant,
very small. The effect size of HC on cerebellar volume is
0.5 mL. With a mean cerebellar volume of 28.4 mL in the
control infants, this would mean a decrease of 1.8%. For total
brain volume, the same calculation would lead to a decrease
of 3.3% (mean volume 378.2 mL, effect size 12.5 mL).
These values are much smaller than those presented by
Tam et al,12 and this difference may be partially explained
by the concomitant use of dexamethasone and HC in part
of their cohort.
Dexamethasone has long been known to have a detrimental
effect on brain growth and maturation in the preterm infant
and has been extensively studied in animal experiments.26,27
There are several hypotheses on why there is such a difference
in adverse long-term effects between dexamethasone and
HC. First, dexamethasone mainly interacts with the gluco-
corticoid receptor of the brain, whereas HC primarily usesBrain Volumes in Preterm Infants 669
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corticoid receptor leads to adverse neuronal effects.29 Second,
during gestation, the enzyme 11b-hydroxysteroiddehydroge-
nase-2 is widely expressed in the fetal or preterm brain.
This enzyme will metabolize the active HC to the inactive
11-dehydro form, thus lowering the active dosage and pro-
tecting the developing brain from excessive corticosteroid ex-
posure.30,31 Dexamethasone is a synthetic glucocorticoid,
and there is no equivalent enzyme for dexamethasone in
the human brain. Third, the effective dosage of HC given is
often lower than the comparable dosage dexamethasone, re-
sulting in a lower cumulative dosage that can cause toxic
effects.32,33 Our standard dose scheme of a total 72.5 mg/kg
HC is substantially higher than in most other studies report-
ing on HC use, where total doses between 6 and 30 mg/kg
were given.33 However, the equivalent dosage of dexametha-
sone in our patients would be approximately 2-3 mg/kg.
Most trials reporting on dexamethasone used higher dosage
schemes.32 Another possible cause for a difference in accu-
mulation is the shorter biological half-life of HC (8-12 hours)
compared with dexamethasone (36-72 hours).34 Again, this
could explain a difference in toxic effects.
There are several limitations to our study. First, the studywas
retrospective, limiting our ability to detect confounders. Sec-
ond, 2 different acquisition protocols were used; however, in-
fants were matched within protocol. Third, we excluded
infants with cystic parenchymal brain lesions, which may
have selected healthier infants but did avoid the possible effect
of large whitematter lesions on cerebellar volumes.22,35 Fourth,
we cannot comment on the underlying microstructure of the
brain, which may be altered by HC exposure. And last, this
was a short-term, structural study; we did not evaluate the
relationshipofbrain volume toneurodevelopmental outcomes.
In conclusion, we could not demonstrate any differences in
brain volumes between children treated with HC for BPD
and nontreated controls at term-equivalent age in this co-
hort. Combined with the earlier reported lack of effect on
long-term developmental outcome, HC seems to be a safer
alternative than dexamethasone in the treatment of BPD. n
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The observation of mental retardation in 5 offspring of a woman with a diagnosis of poorly-controlled phenyl-ketonuria (PKU) was the first report of the hypothesis that abnormal phenylalanine metabolism during preg-
nancy could lead to development disabilities in offspring who are not affected by PKU. The condition in infants
born to women with poorly controlled PKU was given the confusing term maternal PKU, even though it applies
to the infant. Subsequent studies have clearly shown the relationship between persistently elevated plasma phenyl-
alanine in mothers and the congenital anomalies and developmental disabilities that result in the offspring. With
the success of newborn screening and the dietary management of PKU, many women with PKU have had healthy
offspring if they are rigorous in their phenylalanine control at the time of conception and throughout their preg-
nancy. Because compliance with PKU treatment falls off significantly as patients enter their teenage years, a major
effort to counsel females about their risk for abnormal infants is necessary. Young adult females with PKU who are
in poor metabolic control should be offered referral to a metabolic genetic clinic and contraception until they have
achieved good control. New oral pharmaceuticals and injectable enzymes replacement therapies for patients with
PKU, which have been approved or are in late clinical trials, will offer previously unavailable therapeutic options
to prevent the effects of maternal PKU.
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Table II. Brain volumes for the different tissue classes, per segmentation method, uncorrected for postmenstrual age at
time of scanning, gestational age, or birth weight
Warfield et al14 method Anbeek et al15,16 method
HC (n = 19) Control (n = 19) HC (n = 54) Control (n = 54)
Cortical gray matter, mL (SD) 172 (32) 183 (38) 153 (22) 158 (17)
Unmyelinated white matter, mL (SD) 177 (27) 194 (33) 145 (23) 150 (21)
Cerebellum, mL (SD) 23 (4) 24 (5) 28 (4) 30 (3)
Cerebrospinal fluid, mL (SD) 49 (18) 57 (27) 101 (18) 101 (14)
Total brain tissue volume, mL (SD) 377 (57) 403 (64) 355 (39) 369 (34)
Intracranial volume, mL (SD) 426 (64) 460 (73) 455 (52) 471 (44)
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